The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group

Dmoszynska, Anna; Walter-Croneck, Adam; Hus, Iwona; Grzasko, Norbert; Manko, Joanna; Jedrzejczak, Wieslaw Wiktor; Charlinski, Grzegorz; Usnarska-Zubkiewicz, Lidia; Skotnicki, Aleksander; Wolska-Smolen, Teresa; Piszcz, Jaroslaw; Kloczko, Janusz

doi:10.1016/j.leukres.2010.05.003

« Previous Next »Leukemia Research
Volume 34, Issue 10 , Pages 1330-1335, October 2010

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group

Anna Dmoszynska
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
- Corresponding author. Tel.: +48 81 53 45 468; fax: +48 81 53 45 605.
Adam Walter-Croneck
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
Iwona Hus
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
Norbert Grzasko
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
Joanna Manko
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
Wieslaw Wiktor Jedrzejczak
- Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
Grzegorz Charlinski
- Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
Lidia Usnarska-Zubkiewicz
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland
Aleksander Skotnicki
- Department of Haematology, Collegium Medicum, Jagiellonian University, Krakow, Poland
Teresa Wolska-Smolen
- Department of Haematology, Collegium Medicum, Jagiellonian University, Krakow, Poland
Jaroslaw Piszcz
- Department of Haematology, Medical University of Bialystok, Poland
Janusz Kloczko
- Department of Haematology, Medical University of Bialystok, Poland

Received 25 November 2009; received in revised form 26 March 2010; accepted 7 May 2010. published online 07 March 2011.

Abstract

Multiple myeloma (MM) remains an incurable disease, but response rates to new drugs are promising, offering the majority of patients a significant prolongation of overall survival.

The objective of this study was to evaluate time to progression (TTP), event-free survival (EFS), and overall survival (OS) in MM patients treated with a combination of cyclophosphamide (CY), thalidomide (THAL) and dexamethasone (DEX).

This study included 132 untreated and relapsing/resistant patients treated with the low-thalidomide dose CTD regimen. The patients received CY 500mg/m² i.v. or 625mg/m² orally at day 1, THAL 100mg/day á la longue and DEX 20mg/day at days 1–4 and 8–11, every 28 days. Patients received 6–9 cycles; ORR by 3 months was 59.1%, by 6 months 65.6% and by 9 months 75.6%. In patients responding to CTD therapy (CR, nCR, PR), the probability of survival for 20 months was 89.3%. The outpatient low-thalidomide dose CTD regimen is well tolerated and produces a significant response rate both in untreated and relapsing/resistant MM patients.